Jupiter Neurosciences expands Nugevia addressable market

Jupiter Neurosciences (JUNS) announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia consumer longevity product line. This initiative reinforces Jupiter’s dual-engine strategy, combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As GLP-1 adoption accelerates globally, Jupiter sees an opportunity to serve a growing population seeking science-backed, pharmaceutical-grade solutions that extend beyond weight loss alone.